Pinnacle raises $89M for oral peptides matching biologics, cagrilintide shows Phase 3 obesity results, and higher-dose Wegovy achieves 21% weight loss.
10 stories · Covering industry, clinical-trials, research, regulatory
The peptide space continues to dominate headlines with clinical breakthroughs, regulatory drama, and growing public scrutiny. Pinnacle Medicines secured $89M in funding to develop oral peptides that match injectable biologics in efficacy — a potential game-changer for asthma and immunology. On the clinical front, cagrilintide posted strong Phase 3 monotherapy results for obesity, and higher-dose Wegovy (7.2 mg) demonstrated 21% mean weight loss in the STEP UP trial. Meanwhile, the cultural conversation around peptides is intensifying, with GQ profiling the retatrutide hype among fitness influencers and CBC Radio calling injectable peptides 'a giant scam.'
OrbiMed-incubated startup revealed $89M in funding to develop oral peptide drugs with biologic-level efficacy. Lead program targets asthma and is on track for clinical trials.
Novo Nordisk's long-acting amylin analog produced significant weight loss as standalone treatment in a 68-week double-blind trial, strengthening its profile ahead of the CagriSema FDA decision.
Phase IIIb results show investigational 7.2 mg semaglutide dose produced 21% mean weight loss in adults with obesity without diabetes, with a tolerable safety profile.
Industry analysis highlights CagriSema (cagrilintide + semaglutide) Phase 3 data showing 14.2% weight loss in type 2 diabetes adults, positioning it as a major Novo Nordisk pipeline asset.
Deep dive into the retatrutide hype cycle triggered by Andrew Huberman's endorsement and looksmaxxing influencers. Frames the triple-agonist as potentially more consequential than Ozempic.
CBC investigation compares the peptide trend to historical pseudoscience, with scientists emphasizing no large-scale human trials exist for peptides sold by influencers.
Psychiatric Times provides educational review of the incretin system covering the shift toward oral nonpeptide small-molecule GLP-1 RAs and triple agonists expected within 1-2 years.
Three former officials maintain the 2023 decision to deem 19 peptides unsafe for compounding was grounded in documented safety concerns, countering Kennedy's claims on Joe Rogan.
Analysis covers Novo's competitive positioning including ORION study results comparing oral semaglutide against orforglipron, plus up to 48% price cuts in India.
WeightWatchers began offering oral Wegovy with promotional pricing. Clinical trials showed 13.6% body weight loss with oral formulation versus 14.9% injectable.